

Investigating Febrile Polyserositis: An Unusual Case of Idiopathic Hypereosinophilic Syndrome

<u>Inês Rueff Rato</u>¹, Joana Rigor¹, Paula Ferreira¹, Joana Laranjinha², Gualter Santos-Silva³, Daniela Martins-Mendes^{1,4,5} ¹ Internal Medicine Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, Porto, Portugal

² Infectious Diseases, Hospital Pedro Hispano, Porto, Portugal

³ Cardiology Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, Porto, Portugal

⁴Biomedicine Department, Faculty of Medicine of Porto University, Porto, Portugal

⁵i3S - Institute for Research and Innovation of Porto University, Porto, Portugal

Doi: 10.12890/2021_002426- European Journal of Case Reports in Internal Medicine - © EFIM 2021

Received: 26/02/2021 Accepted: 15/03/2021 Published: 02/04/2021

How to cite this article: Rueff Rato I, Rigor J, Ferreira P, Laranjinha J, Santos-Silva G, Martins-Mendes D. Investigating febrile polyserositis: an unusal case of idiopathic hypereosinophilic syndrome. *EJCRIM* 2021;8: doi:10.12890/2021_002426.

Conflicts of Interests: The Authors declare that there are no competing interests. Acknowledgements: The authors would like to thank Unilabs and Dr Susana Guimarães for providing the pathology images. This article is licensed under a Commons Attribution Non-Commercial 4.0 License

ABSTRACT

Hypereosinophilic syndrome (HES) is a heterogenous group of diseases characterized by abnormal accumulation of eosinophils in the blood or peripheral tissues. It can affect all organs and therefore clinical manifestations are highly variable. We describe the case of a 38-yearold man admitted for febrile polyserositis. He developed cardiac tamponade requiring pericardiocentesis complicated by left ventricle perforation which was successfully repaired. He presented mild peripheral eosinophilia. Bronchoalveolar lavage evidenced eosinophilia alveolitis, and pleural and pericardium histopathology revealed the presence of abundant eosinophils. All other causes of tissue eosinophilia were excluded and the diagnosis of idiopathic HES was made. The patient was started on glucocorticoids with resolution of symptoms. This case report describes a rare but potentially fatal presentation of HES and demonstrates the difficulty and delay in diagnosis when peripheral hypereosinophilia is absent.

LEARNING POINTS

- Hypereosinophilic syndrome (HES) is characterized by abnormal accumulation of eosinophils in the blood or peripheral tissues.
- The clinical manifestations of HES are highly variable.
- It may be difficult to diagnose HES when peripheral hypereosinophilia is absent.

KEYWORDS

Hypereosinophilic syndrome, polyserositis, eosinophilic alveolitis, eosinophilic pleurisy, eosinophilic pericarditis

INTRODUCTION

Hypereosinophilic syndrome (HES) is a heterogenous group of rare diseases characterized by abnormal accumulation of eosinophils in the blood or peripheral tissues ^[1]. Any system can be affected, but the most common are the cutaneous, cardiovascular, pulmonary and haematological systems ^[2]. Tissue damage is more likely to occur when the absolute eosinophil count (AEC) exceeds 1500/µl, but peripheral blood eosinophilia does not accurately predict the risk of organ damage. Clinical manifestations are highly variable, ranging from asymptomatic eosinophilia to end-organ failure, developing insidiously or acutely with rapid progression ^[2,3]. Glucocorticoids are used as a



first-line agent followed by the introduction of a steroid-sparing agent if needed^[3]. Imatinib mesylate and other immunomodulatory agents have shown promising results^[2].

CASE DESCRIPTION

A 38-year-old male chef was admitted to the emergency department with dyspnoea on moderate exertion and a 1-month history of pleuritic chest pain with progressive worsening. He had experienced evening fever since the previous week, dry cough, asthenia, and an episode of paroxysmal nocturnal dyspnoea the night before admission. He had no previous diseases and was not taking regular medication, but did have contact with a patient being treated for active pulmonary tuberculosis 3 years previously. On physical examination, he was febrile, tachycardic, tachypnoeic and had respiratory insufficiency requiring supplemental oxygen. Pulmonary auscultation demonstrated absent breath sounds in both lung bases. The remaining physical examination was unremarkable, including the skin and testis. Laboratory findings revealed eosinophil count 230/µl (<700), C-reactive protein 17 mg/dl (<0.5), sedimentation rate 85 mm/hr (<15) and N-terminal proB-type natriuretic peptide 55 pg/ml (<125). There was bilateral pleural effusion on chest radiography (*Fig. 1A*) and computed tomography (CT) angiography of the thorax showed pleural and pericardial effusion. There was vestigial intraperitoneal free fluid on abdominal ultrasound. The electrocardiogram was unremarkable. The patient was hospitalized for febrile polyserositis. The transthoracic echocardiogram revealed moderate pericardial effusion with signs of haemodynamic compromise (*Fig. 1B*) resulting in cardiac tamponade. The patient required pericardiocentesis which was complicated by left ventricle perforation, followed by cardiac arrest and successful emergent surgical correction.



After a period of recovery in the surgical ward, the patient was readmitted to internal medicine care for further study. We were able to exclude infectious, autoimmune, endocrine and haematological aetiologies (*Table 1*). The patient tested positive on an interferon-gamma release assay (IGRA). CT scanning of the thorax, abdomen and pelvis as well as a positron emission tomography scan revealed no additional findings.



Pleural fluid examination showed characteristics of exudate with mononuclear predominance ($1043/\mu$ l leucocytes with 55.7% mononuclear cells). Bronchoalveolar lavage evidenced eosinophilic alveolitis (6.2% eosinophils) with negative cultures. Histopathological examination of pleura was consistent with subacute pleurisy with eosinophils (*Fig. 2*), and pericardium histopathology revealed subacute fibrinous pericarditis with abundant eosinophils (*Fig. 3*). The peak of AEC in peripheral blood was 830 cells/µl (*Fig. 4*). We did not find any genetic rearrangements of the PDGFRA or PDGFRB genes on peripheral blood. Based on these findings, the diagnosis of idiopathic HES was made and the patient was started on 1 mg/kg/day of prednisolone. Tuberculosis prophylaxis with isoniazid was also instituted. He showed clinical improvement within the next few days and was discharged home. The dose of corticosteroid was gradually tapered and discontinued after 6 months. Five years later, the patient remains on regular follow-up with no evidence of disease recurrence.



Figure 2 (A) Skeletal muscle of the chest wall and pleura thickened by fibrosis and inflammatory infiltrate. (B) Thickened pleura, with inflammatory infiltrate rich in eosinophils

Figure 3 (A) Thickened pericardium, with fibrinoleucocyte exudate and subacute haemorrage and underlying fibrosis. (B) Eosinophilic infiltrate



Figure 4. Absolute eosinophil count during hospital admission



	Patient	Reference
General		
Haemoglobin (g/dl)	12.8	13.0-18.0
Leucocyte count (10³/µl)	11.22	3.8-10.6
Neutrophils	7.68	1.3-8.8
Eosinophils	0.83	<0.7
Platelet count (103/µl)	336	150-440
Creatinine (mg/dl)	0.76	0.67-1.17
LDH (U/I)	146	135-225
C-reactive protein (mg/dl)	17	<0.5
Sedimentation rate (mm/hr)	85	<15
Troponin T (ng/l)	11	5-14
NT-proBNP (pg/ml)	55	<125
TSH (μIU/mI)	2.30	0.27-4.2
Vitamin B12 (pg/ml)	474	197-771
Folate (ng/ml)	12	4.6-18.7
Infection		
Blood (×4), pleural fluid and bronchoalveolar lavage microbiology	Negative	
Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila, Rickettsia conorii, Brucella, Borrelia, Treponema pallidum	Negative	
Hepatitis A, B, C, HIV	Negative	
Sputum, pleural fluid and bronchoalveolar lavage for Mycobacterium tuberculosis	Negative	
Interferon-gamma release assay	Positive	
Cytomegalovirus, parvovirus, Epstein–Barr virus, herpes simplex and varicella zoster virus	Negative	
Echinococcus granulosus	Negative	
Stool for Giardia lamblia, Cryptosporidium	Negative	
Immunology		
Immunoglobulins G, M, A, E	Within the reference range	
Serum protein electrophoresis, C3, C4	Within the reference range	
Antinuclear antibodies, anti-double-stranded DNA, rheumatoid factor, antineutrophil cytoplasmic antibodies	Within the reference range	
Haematology and Oncology		
PDGFRA gene mutations	Negative	
Karyotype	46,XY[20]	
Bone marrow aspiration and biopsy	No alterations found	
Human chorionic gonadotropin (mIU/ml)	<2.0	0-2

Table 1. Laboratory findings

Values in red are out of range



DISCUSSION

Cardiac involvement in HES is common ^[4], but pericardial involvement is estimated to be less than 10% ^[5]. There are several case reports on HES presenting as cardiac tamponade ^[4-9], but to our knowledge this is the first case without peripheral hypereosinophilia. Our patient presented with only mild peripheral eosinophilia which led to a delay in diagnosis. Only when histopathology reports showed tissue damage due to presence of eosinophils did the diagnosis became apparent. In the setting of HES, patients usually present with peripheral blood hypereosinophilia and eosinophilia-related target organ damage^[3]. However, it is worth mentioning that the diagnostic criteria include tissue infiltration that is extensive in the subjective opinion of a pathologist ^[4]. The diagnosis of idiopathic HES was established as all other known causes of eosinophil dysfunction were excluded. The aim of therapy in HES is to reduce the eosinophilic granulocyte count in tissues, and glucocorticoids are generally recommended as first-line therapy ^[4,7]. Our patient responded well to prednisolone with iatrogenic diabetes during treatment that was well controlled with metformin and sitagliptin. However, if prednisolone is not suitable, many other regimens are available, including steroid-sparing agents, a tyrosine-kinase inhibitor (imatinib) or immunomodulatory agents ^[2,3]. Because of profound immunosuppression during treatment, it is important that infectious diseases are excluded. Our patient had previous contact with a patient being treated for active pulmonary tuberculosis a few years earlier and tested positive for IGRA. Therefore, it was mandatory to exclude active infection and start treatment for latent tuberculosis.

CONCLUSION

The authors consider that this case is unique because of the severity of organ dysfunction (eosinophilic alveolitis, pleurisy and pericarditis) in the absence of hypereosinophilia. Clinical expertise and attention are needed in the diagnosis of rare diseases, especially with atypical presentations, to ensure the best outcomes.

REFERENCES

- 1. Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, Weller PF, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012;130(3):607–612.e9.
- 2. Curtis C, Ogbogu P. Hypereosinophilic syndrome. Clin Rev Allergy Immunol 2015;**50**(2):240–251.
- 3. Hsieh F. Hypereosinophilic syndrome. Ann Allergy Asthma Immunol 2014;112(6):484–488.
- 4. Moza A, Sheikh M, Rock-Willoughby J, Cooper C, Kanjwal Y. Idiopathic hypereosinophilic syndrome presenting with cardiac tamponade. *Heart Lung* 2012;41(6):e15-e17.
- 5. Fernandez A, Ahmed S, Duncan B, Firshein S, Kluger J. Cardiac tamponade: a rare complication of idiopathic hypereosinophilic syndrome. J Cardiovasc Med 2009;10(2):188–191.
- 6. Beynel P, Nesme P, Perol M, Guerin JC. [Association of idiopathic eosinophilic pleurisy and a severe pericardial effusion]. Rev Mal Respir 1997;14(3):218–220.
- 7. Wu P, Chen Y, Zhang H, Li C. Idiopathic hypereosinophilic syndrome presenting with multiple organ damage. *Medicine* 2019;98(10):e14532.
- 8. Kazama R, Okura Y, Hoyano M, Toba K, Ochiai Y, Ishihara N, et al. Therapeutic role of pericardiocentesis for acute necrotizing eosinophilic myocarditis with cardiac tamponade. Mayo Clin Proc 2003;78(7):901–907.
- 9. Kiani R, Naghavi B, Amin A, Sadeghpour A, Zahedmehr A, Firouzi A, et al. Central nervous system and cardiac involvement in the hypereosinophilic syndrome: a case report. Immunol. Invest 2020; 1–7. doi: 10.1080/08820139.2020.1758131. Online ahead of print.